Also new today out of #FallClinical2025 in Vegas:
Lebrikizumab-lbkz (Ebglyss; EliLillyandCo) demonstrated similar levels of #skin clearance in patients with #atopicdermatitis when administered once every 8 weeks compared to every 4 weeks.
MORE: www.contemporarypediatrics.com/view/fall-cl...
0
0
0
0